NCT01282502View on ClinicalTrials.gov

Midostaurin (PKC412) for Locally Advanced Rectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

December 31, 2018

Conditions
Adenocarcinoma of the Rectum
Interventions
DRUG

Midostaurin

50 mg BID for 8 cycles

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01282502 - Midostaurin (PKC412) for Locally Advanced Rectal Cancer | Biotech Hunter | Biotech Hunter